__timestamp | Evotec SE | Insmed Incorporated |
---|---|---|
Wednesday, January 1, 2014 | 17990000 | 31073000 |
Thursday, January 1, 2015 | 25166000 | 43216000 |
Friday, January 1, 2016 | 27013000 | 50679000 |
Sunday, January 1, 2017 | 42383000 | 79171000 |
Monday, January 1, 2018 | 57012000 | 168218000 |
Tuesday, January 1, 2019 | 66546000 | 210796000 |
Wednesday, January 1, 2020 | 77238000 | 203613000 |
Friday, January 1, 2021 | 105445000 | 234273000 |
Saturday, January 1, 2022 | 156190000 | 265784000 |
Sunday, January 1, 2023 | 169610000 | 344501000 |
Data in motion
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Insmed Incorporated and Evotec SE have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, reflecting its aggressive expansion and investment in operational capabilities. In contrast, Evotec's expenses grew by approximately 840%, indicating a more measured approach.
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Insmed Incorporated
SG&A Efficiency Analysis: Comparing GSK plc and Insmed Incorporated
Breaking Down SG&A Expenses: Insmed Incorporated vs Sarepta Therapeutics, Inc.
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Insmed Incorporated or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Insmed Incorporated or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Insmed Incorporated vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Insmed Incorporated or Galapagos NV
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Evotec SE
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Evotec SE
Celldex Therapeutics, Inc. or Evotec SE: Who Manages SG&A Costs Better?